Immunoassay Interference Blocker Market Trends

Immunoassay Interference Blocker Market Trends

• The rise in the prevalence of chronic diseases has sparked a corresponding increase in the demand for immunoassay interference blockers. Chronic diseases such as cancer, cardiovascular disorders, diabetes, and autoimmune conditions pose significant challenges in diagnosis and management. Therefore, immunoassays are pivotal in detecting biomarkers associated with these diseases, aiding in early diagnosis, prognosis, and treatment monitoring.
   
• For instance, as per the report published by World Health Organization in September 2023, noncommunicable diseases (NCDs) kill 41 million people each year, equivalent to 74% of all deaths globally. Each year, 17 million people die from NCD before age 70. Cardiovascular diseases account for most NCD deaths, or 17.9 million people annually, followed by cancers, chronic respiratory diseases, and diabetes. Thus, the escalating prevalence of chronic diseases underscores the importance of advanced immunoassay interference blockers in improving patient outcomes and driving innovation in diagnostic technologies that will boost the growth of the market.